ICON plc.
ICLRICLR · Stock Price
Historical price data
Overview
ICON plc is a mission-critical partner in the global drug development ecosystem, dedicated to expanding the possibilities of clinical research through innovative, patient-centric solutions. Since its founding in 1990, the company has grown into the largest CRO by revenue, achieving a market valuation of $8.11 billion by offering end-to-end services from early-phase studies to post-market surveillance. Its strategy is anchored in digital transformation—through platforms like EngageAI and its integrated Digital Platform—and a flexible service model tailored to the unique needs of biotech, pharma, and medical device sponsors, positioning it to capitalize on the growing trend of R&D outsourcing.
Technology Platform
An integrated digital ecosystem including the ICON Digital Platform for trial management, EngageAI for AI-enhanced client feedback, and comprehensive Digital Health Technology services for decentralized and hybrid clinical trials.
Pipeline
47| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Jatenzo | Hypogonadism | Approved | |
| VAS203 + Saline | Traumatic Brain Injury | Phase 3 | |
| BT524 (Part I) + BT524 (Part II) | Congenital Afibrinogenemia | Phase 3 | |
| CureXcell® + Sham injection | Lower Extremity Chronic Ulcers in Diabetics | Phase 3 | |
| EcN-Suspension + Placebo | Infections | Phase 3 |
Opportunities
Risk Factors
Competitive Landscape
ICON competes in a consolidated market against large, full-service CROs like IQVIA, Labcorp (Covance), and Parexel. Its competitive edge lies in its position as the largest pure-play CRO, a unified proprietary technology stack, and a strong reputation for operational delivery, particularly in serving the biotech segment.